Letybo Side Effects
Generic name: letibotulinumtoxinA
Note: This document contains side effect information about letibotulinumtoxinA. Some dosage forms listed on this page may not apply to the brand name Letybo.
Applies to letibotulinumtoxinA: intramuscular powder for injection.
General
The most common adverse reaction occurring in more than 2% of patients was headache. Adverse reactions may occur within the first few days following injection and may have a transient duration of up to several months or longer.[Ref]
Dermatologic
Rare (0.01% to 0.1%): Brow ptosis/heaviness, dry skin, urticaria, folliculitis
Gastrointestinal
Rare (0.01% to 0.1%): Constipation, nausea, oral herpes
Frequency not reported: Dysphagia[Ref]
Immunologic
Uncommon (0.1% to 1%): Anti-drug antibodies
Local
Common (1% to 10%): Injection site reaction
Uncommon (0.1% to 1%): Injection site: Pain, pressure, bruising, swelling, pruritus, mass
Rare (0.01% to 0.1%): Folliculitis, periorbital hematoma, contusion
Frequency not reported: Injection site: Nodule, inflammation, tenderness, erythema, itching, bleeding[Ref]
Metabolic
Rare (0.01% to 0.1%): Increased serum potassium[Ref]
Musculoskeletal
Frequency not reported: Local muscle weakness (expected due to pharmacological action of botulinum toxin in muscle tissue)[Ref]
Ocular
Uncommon (0.1% to 1%): Eyelid ptosis, blepharospasm, periorbital edema
Rare (0.01% to 0.1%): Conjunctival hemorrhage, dry eye, eye pain[Ref]
Respiratory
Common (1% to 10%): Nasopharyngitis, bronchitis
Rare (0.01% to 0.1%): Pharyngeal hypoesthesia, streptococcal pharyngitis, pneumonia, sinusitis[Ref]
Nervous system
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Head discomfort
Rare (0.01% to 0.1%): Migraine, dizziness, paresthesia, visual field defect
Frequency not reported: Procedural headache[Ref]
Frequently asked questions
More about Letybo (letibotulinumtoxinA)
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: skeletal muscle relaxants
Patient resources
Related treatment guides
References
1. (2023) "Product Information. Letybo (letibotulinumtoxinA)." Croma Aesthetics Canada, Ltd
2. (2022) "Product Information. Letybo (letibotulinumtoxinA)." CROMA Australia Pty Ltd, 1
3. (2024) "Product Information. Letybo (letibotulinumtoxinA)." Hugel Aesthetics
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.